KDR and neoplasm: Focusing on the fact that the growth and survival of cancer cells depend on blood supply, we developed tumor angiogenesis-specific CAR-T cells impacting cancers (TACTICs) targeting vascular endothelial growth factor receptor-2 (VEGFR2), which is expressed at high levels in tumor vascular endothelial cells [8].